肿瘤药学2019，Vol.9Issue(5)：771-774,788,5.DOI:10.3969/j.issn.2095-1264.2019.05.14
右丙亚胺对蒽环类药物引起乳腺癌术后患者心脏毒性的预防研究
Preventive Effects of Dexrazoxane on Anthracycline-Induced Cardiac Toxicity in Post-surgery Breast Cancer Patients
赵丽 1葛亚楠 2荆全民1
作者信息
- 1. 北部战区总医院心内科,辽宁 沈阳,110016
- 2. 北部战区总医院肿瘤科,辽宁 沈阳,110016
- 折叠
摘要
Abstract
Objective To investigate the preventive and therapeutic effects of dexrazoxane on cardiotoxicity of breast cancer patients induced by anthracycline drugs. Methods The selected post-surgery breast cancer patients receiving anthracycline chemotherapy were di-vided into observation group and control group by random number method. The patients in observation group were given intravenous drip of dexrazoxane before anthracycline treatment. The serum cardiac troponin T (cTnT), serum B-type natriuretic peptide (BNP), creatine kinase isoenzyme (CK-MB), and left ventricular ejection fraction (LVEF) after 6 months, 12 months, and 24 months of treatment were compared be-tween the two groups. Moreover, the adverse reactions of chemotherapy and abnormal changes of electrocardiogram were compared between the two groups. Results Compared with before treatment, the serum cTnT level of both groups increased after treatment, and the difference was statistically significant (P<0.05). After 6 months, 12 months, and 24 months of treatment, the serum cTnT levels were significantly lower in observation group than in control group (P<0.05). Compared with before treatment, the serum BNP level increased in the control group after 6 months of treatment, but in the observation group, it increased after 12 months of treatment. There was a statistical difference between the two groups (P<0.05). Compared with before treatment, there was no significant difference in serum CK-MB in the observation group after treatment (P>0.05). The serum CK-MB level in the control group increased after 24 months of treatment (P<0.05). The LVEF level in the observation group decreased after 24 months of treatment as compared with before treatment (P<0.05). The levels of LVEF in the obser- vation group after 12 and 24 months of treatment were all significantly higher than those in the control group (P<0.05). The rate of abnormal ECG was lower in observation group (18.9%) than in control group (34.5%) (P<0.05). No significant differences were found in adverse reac-tions of chemotherapy between the two groups (P>0.05). Conclusion Dexrazoxane has protective effect on cardiac toxicity induced by an-thracycline chemotherapeutics in post-surgery breast cancer patients, with tolerable adverse reaction.关键词
右丙亚胺/乳腺癌/心脏毒性/蒽环类药物Key words
Dexrazoxane/Breast cancer/Cardiotoxicity/Anthracycline分类
医药卫生引用本文复制引用
赵丽,葛亚楠,荆全民..右丙亚胺对蒽环类药物引起乳腺癌术后患者心脏毒性的预防研究[J].肿瘤药学,2019,9(5):771-774,788,5.
